StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
In April, Revolution shares rocketed 54% after the company announced dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating Rasonque in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. In the overall intent-to-treat population of the Phase III RASolute 302 trial (NCT06625320), daraxonrasib showed a median overall survival (OS)…
Revolution Medicines' stock remained virtually unchanged after the FDA approved its breakthrough oral therapy Rasonque, the first RAS inhibitor for pancreatic cancer. Investors are uncertain if the high price point will drive the anticipated sales. The stock rose 2.65% on Thursday to $221.15, but fell 6% on Friday, ending the week at $207.88 amid market declines after Fed Chair Kevin Warsh hinted at potential rate hikes to curb inflation.
Rasonque is a first-in-class inhibitor targeting multiple RAS mutations in metastatic pancreatic adenocarcinoma (PDAC) patients who have undergone at least one prior systemic therapy or are not candidates for multi-agent therapy. In a pivotal Phase III trial, daraxonrasib demonstrated a median overall survival of 13.2 months, outpacing standard chemotherapy by half.
The FDA approved Rasonque, receiving Breakthrough Therapy and Orphan Drug designations, and processed its application within months rather than the usual 10-12. Revolution expects sales to surge from $12.7 million in Q3 to $989 million by 2028, potentially positioning the company as the next major player in oncology.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
